Septerna is proud to announce an exciting funding milestone, having raised $2,400,000,000 in its latest round of financing. This momentous achievement underscores the unwavering confidence that investors and partners have in Septerna’s groundbreaking approach and its mission to bring transformative GPCR medicines to patients worldwide. By merging the latest advances in biochemical, structural, and computational drug discovery, Septerna has successfully built an industrialized platform that precisely controls and modulates GPCR biology and pharmacology. The infusion of capital will accelerate the development and expansion of the Native Complex Platform™, a pioneering technology that is opening a new frontier in GPCR small molecule discovery and redefining what is possible in the druggable GPCR landscape.
The substantial funding not only reinforces Septerna’s commitment to innovation but also provides the critical resources necessary to push the boundaries of current drug discovery methods. With this new capital, the company is poised to enhance its research and development capabilities, scale-up manufacturing processes, and explore novel therapeutic avenues that have the potential to change patient lives on a global scale. At the same time, this exciting phase opens up opportunities for talented scientists, drug hunters, and business professionals who share a passion for breakthrough innovations in healthcare. Septerna invites those who are energized by teamwork and driven by a desire to drive meaningful change. Join us as we set the stage for a new era in GPCR medicine, where the promise of future therapies is rapidly turning into a tangible reality for patients across the globe.
